b Tested in sodium chloride 0.9%.
c Tested in both dextrose 5% and sodium chloride 0.9%.
d Tested in sterile water for injection.
e Tested in bacteriostatic sodium chloride 0.9% preserved with benzyl alcohol 0.9%.
f Tested as the premixed infusion solution.
g Lyophilized formulation tested.
h Refer to Appendix for the composition of parenteral nutrition solutions. TNA indicates a 3-in-1 admixture, and TPN indicates a 2-in-1 admixture.
j In dextrose 5% infused at 1.2 mL/hr.
k Tested in dextrose 5% in sodium chloride 0.45%.
l Tested in Ringer’s injection, lactated.
m Sulbactam component. Sulbactam in a 1:1 fixed-ratio concentration with durlobactam.
n Test performed using the formulation WITHOUT edetate disodium.
o Tested in either dextrose 5% or in sodium chloride 0.9%, but the report did not specify which solution.
p Tested in a 1:1 mixture of (1) dextrose 5% and dextrose 5% in sodium chloride 0.45% with and without potassium chloride 20 mEq/L and also in (2) dextrose 10% in sodium chloride 0.45% with and without potassium chloride 20 mEq/L.
r Piperacillin component. Piperacillin in an 8:1 fixed-ratio concentration with tazobactam.
t Quinupristin and dalfopristin components combined.
u Ceftolozane component. Ceftolozane in a 2:1 fixed-ratio concentration with tazobactam.
v Meropenem component. Meropenem in a 1:1 fixed-ratio concentration with vaborbactam.
w Test performed using the formulation WITH edetate disodium.
x Imipenem component. Imipenem in a 2:2:1 fixed-ratio concentration with cilastatin and relebactam.
y Tested with lidocaine HCl (AB) 8 mg/mL.
z Tested with nitroglycerin (LY) 0.4 mg/mL.